|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DRG2 |
Gene summary for DRG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DRG2 | Gene ID | 1819 |
| Gene name | developmentally regulated GTP binding protein 2 | |
| Gene Alias | DRG2 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A8MZF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1819 | DRG2 | P16T-E | Human | Esophagus | ESCC | 7.42e-35 | 5.12e-01 | 0.1153 |
| 1819 | DRG2 | P17T-E | Human | Esophagus | ESCC | 1.02e-15 | 3.93e-01 | 0.1278 |
| 1819 | DRG2 | P19T-E | Human | Esophagus | ESCC | 7.18e-14 | 8.70e-01 | 0.1662 |
| 1819 | DRG2 | P20T-E | Human | Esophagus | ESCC | 9.42e-26 | 5.02e-01 | 0.1124 |
| 1819 | DRG2 | P21T-E | Human | Esophagus | ESCC | 4.19e-41 | 7.61e-01 | 0.1617 |
| 1819 | DRG2 | P22T-E | Human | Esophagus | ESCC | 1.89e-35 | 6.20e-01 | 0.1236 |
| 1819 | DRG2 | P23T-E | Human | Esophagus | ESCC | 8.89e-32 | 6.39e-01 | 0.108 |
| 1819 | DRG2 | P24T-E | Human | Esophagus | ESCC | 3.44e-32 | 6.18e-01 | 0.1287 |
| 1819 | DRG2 | P26T-E | Human | Esophagus | ESCC | 7.73e-27 | 4.71e-01 | 0.1276 |
| 1819 | DRG2 | P27T-E | Human | Esophagus | ESCC | 3.62e-32 | 4.92e-01 | 0.1055 |
| 1819 | DRG2 | P28T-E | Human | Esophagus | ESCC | 1.52e-20 | 3.05e-01 | 0.1149 |
| 1819 | DRG2 | P30T-E | Human | Esophagus | ESCC | 3.62e-21 | 6.59e-01 | 0.137 |
| 1819 | DRG2 | P31T-E | Human | Esophagus | ESCC | 2.85e-30 | 5.85e-01 | 0.1251 |
| 1819 | DRG2 | P32T-E | Human | Esophagus | ESCC | 8.89e-66 | 1.36e+00 | 0.1666 |
| 1819 | DRG2 | P36T-E | Human | Esophagus | ESCC | 5.44e-19 | 4.55e-01 | 0.1187 |
| 1819 | DRG2 | P37T-E | Human | Esophagus | ESCC | 5.12e-34 | 6.28e-01 | 0.1371 |
| 1819 | DRG2 | P38T-E | Human | Esophagus | ESCC | 5.79e-12 | 4.84e-01 | 0.127 |
| 1819 | DRG2 | P39T-E | Human | Esophagus | ESCC | 1.34e-19 | 3.34e-01 | 0.0894 |
| 1819 | DRG2 | P40T-E | Human | Esophagus | ESCC | 1.28e-13 | 3.04e-01 | 0.109 |
| 1819 | DRG2 | P42T-E | Human | Esophagus | ESCC | 2.89e-28 | 5.57e-01 | 0.1175 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00217629 | Breast | Precancer | substantia nigra development | 15/1080 | 44/18723 | 1.12e-08 | 7.98e-07 | 15 |
| GO:00309018 | Breast | Precancer | midbrain development | 20/1080 | 90/18723 | 1.50e-07 | 7.93e-06 | 20 |
| GO:00488578 | Breast | Precancer | neural nucleus development | 16/1080 | 64/18723 | 4.76e-07 | 2.11e-05 | 16 |
| GO:002176214 | Breast | IDC | substantia nigra development | 18/1434 | 44/18723 | 1.11e-09 | 1.07e-07 | 18 |
| GO:004885713 | Breast | IDC | neural nucleus development | 21/1434 | 64/18723 | 5.35e-09 | 4.28e-07 | 21 |
| GO:003090112 | Breast | IDC | midbrain development | 24/1434 | 90/18723 | 4.35e-08 | 2.87e-06 | 24 |
| GO:00703713 | Breast | IDC | ERK1 and ERK2 cascade | 43/1434 | 330/18723 | 4.28e-04 | 5.84e-03 | 43 |
| GO:00486592 | Breast | IDC | smooth muscle cell proliferation | 26/1434 | 184/18723 | 1.77e-03 | 1.72e-02 | 26 |
| GO:00703733 | Breast | IDC | negative regulation of ERK1 and ERK2 cascade | 14/1434 | 78/18723 | 2.21e-03 | 2.06e-02 | 14 |
| GO:00486602 | Breast | IDC | regulation of smooth muscle cell proliferation | 25/1434 | 180/18723 | 2.71e-03 | 2.41e-02 | 25 |
| GO:00703722 | Breast | IDC | regulation of ERK1 and ERK2 cascade | 37/1434 | 309/18723 | 4.53e-03 | 3.49e-02 | 37 |
| GO:002176223 | Breast | DCIS | substantia nigra development | 17/1390 | 44/18723 | 5.72e-09 | 4.76e-07 | 17 |
| GO:004885723 | Breast | DCIS | neural nucleus development | 20/1390 | 64/18723 | 1.87e-08 | 1.29e-06 | 20 |
| GO:003090122 | Breast | DCIS | midbrain development | 23/1390 | 90/18723 | 1.10e-07 | 5.93e-06 | 23 |
| GO:007037111 | Breast | DCIS | ERK1 and ERK2 cascade | 41/1390 | 330/18723 | 8.11e-04 | 9.32e-03 | 41 |
| GO:007037311 | Breast | DCIS | negative regulation of ERK1 and ERK2 cascade | 14/1390 | 78/18723 | 1.65e-03 | 1.64e-02 | 14 |
| GO:004865911 | Breast | DCIS | smooth muscle cell proliferation | 25/1390 | 184/18723 | 2.42e-03 | 2.18e-02 | 25 |
| GO:004866011 | Breast | DCIS | regulation of smooth muscle cell proliferation | 24/1390 | 180/18723 | 3.74e-03 | 3.01e-02 | 24 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DRG2 | SNV | Missense_Mutation | c.215N>G | p.Ser72Cys | p.S72C | P55039 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DRG2 | SNV | Missense_Mutation | c.853N>A | p.Glu285Lys | p.E285K | P55039 | protein_coding | tolerated(0.16) | benign(0.075) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
| DRG2 | insertion | Nonsense_Mutation | novel | c.146_147insTGAGGCGGGATTTTTTTTTTTTTTTTGAGATGGAGTTTCACTGTT | p.Ser49_Ser50insGluAlaGlyPhePhePhePhePheTerAspGlyValSerLeuLeu | p.S49_S50insEAGFFFFF*DGVSLL | P55039 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DRG2 | SNV | Missense_Mutation | c.494N>T | p.Ser165Phe | p.S165F | P55039 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DRG2 | SNV | Missense_Mutation | rs552445784 | c.962G>A | p.Arg321His | p.R321H | P55039 | protein_coding | tolerated(0.41) | benign(0.429) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DRG2 | SNV | Missense_Mutation | novel | c.713A>C | p.Tyr238Ser | p.Y238S | P55039 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DRG2 | SNV | Missense_Mutation | c.747N>A | p.Asp249Glu | p.D249E | P55039 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DRG2 | SNV | Missense_Mutation | novel | c.416N>T | p.Thr139Met | p.T139M | P55039 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DRG2 | SNV | Missense_Mutation | c.611N>G | p.Gln204Arg | p.Q204R | P55039 | protein_coding | tolerated(0.69) | benign(0.006) | TCGA-D1-A16N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| DRG2 | SNV | Missense_Mutation | novel | c.946N>A | p.Glu316Lys | p.E316K | P55039 | protein_coding | tolerated(0.12) | benign(0.059) | TCGA-D1-A16V-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |